Acarbose Cardiovascular Evaluation
The Acarbose Cardiovascular Evaluation (ACE) clinical trial will find out if a drug called acarbose can prevent people with coronary heart disease and impaired glucose tolerance (IGT) from experiencing, or dying from, further heart attacks and strokes.
The ACE trial will also look to see if acarbose, which reduces blood glucose following a meal, can prevent or delay people progressing from IGT to type 2 diabetes.
Coordinated by DTU and funded by Bayer, this phase IV multinational trial began in 2008. It is being conducted in around 150 hospitals in mainland China and Hong Kong. The participating hospitals will be managed on a day-to-day basis through DTU’s ACE Project Office in Beijing.
6,500 people with heart and circulatory disease aged 50 years or older who have impaired glucose tolerance will be recruited to the trial. Each participant will receive a 50mg acarbose tablet or a placebo (dummy drug) three times a day, and will be followed for a minimum of four years.
We expect that results of this trial will be available in 2017.